Commentary: Little evidence of effective prenatal treatment against congenital toxoplasmosis - The implications for testing in pregnancy

International Journal of Epidemiology

Volumn 30, Issue 6, 2001, Pages 1314-1315

  Eskild, Anne ^a   Magnus, Per ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; PLACEBO; PYRIMETHAMINE;

HEALTH CARE; PREGNANCY; TESTING METHOD;

ADULT; BRAIN INJURY; CHILD; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; DENMARK; DISEASE TRANSMISSION; EUROPE; EYE INJURY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; NOTE; PATIENT SELECTION; POPULATION RESEARCH; PREGNANCY; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; TOXOPLASMA GONDII; TREATMENT OUTCOME;

EID: 0035709587     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/30.6.1314     Document Type: Note

References (9)

1. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: Retrospective cohort study of 544 mother-child pairs in Lyon, France
2. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis
3. Treatment of toxoplasmosis during pregnancy: A multicenter study of impact on fetal transmission and children's sequelae at one year of age
4. Congenital toxoplasmosis: Systematic review of evidence of efficacy of treatment in pregnancy
5. Screening for toxoplasmosis in pregnancy: What is the evidence of reducing a health problem?
6. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
7. Neural tube defects in relation to use of folic acid antagonists during pregnancy
8. Screening could seriously damage your health
9. Risk factors for toxoplasma infection in pregnancy. Results from a prospective study in Norway